Just in time for procrastinators, FDA offers DRLS crash course
This article was originally published in The Gold Sheet
Executive Summary
FDA is offering a one-hour crash course June 26 on how to use its new electronic drug registration and listing system (DRLS). The course is designed specifically for people with a pressing need to use the system, but who were caught unawares by the agency's decision to stop accepting paper applications June 1. FDA's Data Standards Council has been offering free six-session webinars, and will run those through September. For more information or to register, email [email protected]. Also on June 1, the agency published final guidance on filing electronic registration and listing submissions, available at www.fda.gov/cder/guidance
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.